+Search query
-Structure paper
Title | Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy. |
---|---|
Journal, issue, pages | Cell, Year 2024 |
Publish date | Oct 21, 2024 |
Authors | Yufei Xiang / Jialu Xu / Briana L McGovern / Anna Ranzenigo / Wei Huang / Zhe Sang / Juan Shen / Randy Diaz-Tapia / Ngoc Dung Pham / Abraham J P Teunissen / M Luis Rodriguez / Jared Benjamin / Derek J Taylor / Mandy M T van Leent / Kris M White / Adolfo García-Sastre / Peijun Zhang / Yi Shi / |
PubMed Abstract | Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as ...Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness costs. We introduce adaptive multi-epitope targeting with enhanced avidity (AMETA), a modular and multivalent nanobody platform that conjugates potent bispecific nanobodies to a human immunoglobulin M (IgM) scaffold. AMETA can display 20+ nanobodies, enabling superior avidity binding to multiple conserved and neutralizing epitopes. By leveraging multi-epitope SARS-CoV-2 nanobodies and structure-guided design, AMETA constructs exponentially enhance antiviral potency, surpassing monomeric nanobodies by over a million-fold. These constructs demonstrate ultrapotent, broad, and durable efficacy against pathogenic sarbecoviruses, including Omicron sublineages, with robust preclinical results. Structural analysis through cryoelectron microscopy and modeling has uncovered multiple antiviral mechanisms within a single construct. At picomolar to nanomolar concentrations, AMETA efficiently induces inter-spike and inter-virus cross-linking, promoting spike post-fusion and striking viral disarmament. AMETA's modularity enables rapid, cost-effective production and adaptation to evolving pathogens. |
External links | Cell / PubMed:39447570 |
Methods | EM (single particle) |
Resolution | 3.6 Å |
Structure data | EMDB-43795, PDB-9arv: |
Chemicals | ChemComp-NAG: |
Source |
|
Keywords | IMMUNE SYSTEM / IgM / nanobody |